| |
| How do you overall rate this meeting? |
| |
|
|
|
|
| |
How do you rate individual topics and presentations?
CZP molecular structure and mode of action (Dr A. Nesbitt) - Content |
| |
|
|
|
|
| |
| CZP molecular structure and mode of action (Dr A. Nesbitt) - Relevance to my clinical |
| |
|
|
|
|
| |
| CZP predicability data (Prof S. Hall) - Content |
| |
|
|
|
|
| |
| CZP predictability data (Prof S. Hall) - Relevance to my clinical |
| |
|
|
|
|
| |
| CZP predictability data from Japanese studies (Dr P. Shane) - Content |
| |
|
|
|
|
| |
| CZP predictability data from Japanese studies (Dr P. Shane) - Relevance to my clinical |
| |
|
|
|
|
| |
| Safety of biologic DMARDs (Dr M. Harigai) - Content |
| |
|
|
|
|
| |
| Safety of biologic DMARDs (Dr M. Harigai) - Relevance to my clinical |
| |
|
|
|
|
| |
| CZP global and regional clinical development (Dr N. de Payrecave and Dr Shao Jing) - Content |
| |
|
|
|
|
Loading...
